What are the drug therapy options for this patient?

The authors’ observations

“Treatment-refractory” schizophrenia has numerous definitions. One that is widely accepted but cumbersome—used in the multicenter clozapine trial1—requires a 5-year absence of periods of good functioning in patients taking an antipsychotic at dosages equivalent to chlorpromazine, 1,000 mg/d. In that time, the patient must have received two or more antipsychotic classes for at least 6 weeks each without achieving significant relief. The Brief Psychiatric Rating Scale (BPRS) score must be at least 45, with item scores of moderate severity for two or more of the following:

- disorganization
- suspiciousness
- hallucinatory behavior
- unusual thought content.

The Clinical Global Impression (CGI) Scale score must be at least 4 (moderately ill). Also, a 6-week trial of haloperidol, with a mean dosage of 60 mg/d:

- must fail to decrease the BPRS score by 20% or to below 35

continued on page 73
or must fail to decrease the CGI severity score to 3 (mildly ill).\(^1\)

In 1990, an international study group defined treatment-refractory schizophrenia as “the presence of ongoing psychotic symptoms with substantial functional disability and/or behavioral deviances that persist in well-diagnosed persons with schizophrenia despite reasonable and customary pharmacological and psychosocial treatment that has been provided for an adequate period.”\(^2\) This definition is far more useful to clinical practice and also considers psychosocial function. Seven levels of treatment response and resistance were suggested, based on presence of positive and negative symptoms, personal and social functioning, and CGI scores.\(^2\)

Meltzer\(^3\) proposed that any person not returning to his or her highest premorbid level of functioning with a tolerable antipsychotic be considered refractory and thus a possible candidate for clozapine therapy.

Ms. G’s illness meets the definition of treatment-refractory schizophrenia. Her CGI score at baseline was 5—severely ill—and several medication trials at sufficient dosages failed to control her positive or negative symptoms. Upon psychotic decompensation, she required prolonged hospitalization and could no longer live independently or work. At this point, she is a possible candidate for clozapine therapy.

Ms. G continued to take clozapine, 300 mg/d, for 2 years while undergoing weekly blood tests for white blood cell counts (WBC) with differentials. She did not require hospitalization for schizophrenia during this time, and her WBC count averaged between 4,000 and 4,500/mm\(^3\), well within the normal range of 3,500 to 12,000/mm\(^3\).

Then one day—after maintaining a relatively stable WBC for several weeks—a blood test revealed a WBC of 2,700/mm\(^3\). Ms. G exhibited no objective signs of immunosuppression, such as fever or infection. Still, the psychiatrist immediately discontinued clozapine.

**Was the treating psychiatrist justified in immediately stopping clozapine after one low WBC reading?**

The authors’ observations

Leukopenia, defined as a WBC <3,000/mm\(^3\), and agranulocytosis, defined as an absolute neutrophil count <500/mm\(^3\), are well-documented adverse reactions to clozapine. Early data on clozapine-associated agranulocytosis cases prior to 1989 suggest that up to 32% were fatal,\(^1\) but relatively few cases have occurred since the Clozaril National Registry was instituted in 1977.\(^4\) Between 1977 and 1997, 585 clozapine-associated agranulocytosis cases were reported in the United States; 19 of these were fatal, suggesting a mortality rate of 3.2% and attesting to the effectiveness of FDA-mandated WBC testing. During this period, 150,409 patients received clozapine.\(^1\)

The agranulocytosis risk does not appear to be
dose-related but declines substantially after the 10th week. Three out of 1,000 patients who take clozapine for 1 year are likely to develop agranulocytosis at the 3- to 6-month mark. Although the incidence continues to drop after month 6, it never reaches zero.

Other severe adverse effects of clozapine include myocarditis associated with cardiac failure, orthostatic hypotension with circulatory collapse, and rhabdomyolysis (Table). Leukocytosis and eosinophilia are generally transient and self-limited but may predict agranulocytosis. The risk of seizure occurs most commonly at dosages greater than 500 mg/d.

Given these potentially fatal effects, the authors’ treatment guidelines call for potential suspension of clozapine therapy when the WBC is consistently <3,000/mm³ (Algorithm).

Approximately 3 weeks later, Ms. G was hospitalized for renewed severe paranoia and command-type auditory hallucinations accompanied by prominent mood lability, avolition, and thought disorganization. During her 7-week hospitalization, she underwent sequential and sometimes overlapping trials of:

- ziprasidone, 160 mg bid
- risperidone, 3 mg bid
- trifluoperazine, 3 mg bid
- haloperidol, 10 mg bid
- divalproex sodium, 500 mg bid
- and carbamazepine, 400 mg bid.

None of these trials significantly improved her psychosis or mood.

At this point, the treating psychiatrists faced a difficult but clear decision: Ms. G was rechallenged on clozapine, 25 mg nightly, titrated again to 300 mg nightly. After she provided informed consent, her WBC was monitored twice daily—morning and evening—for agranulocytosis and to examine WBC patterns. Her average daily WBC counts were 4,200/mm³ in the morning and 5,500/mm³ at night. No physical signs of agranulocytosis emerged.

One week after restarting clozapine, Ms. G became less paranoid and socially more appropriate. Her thought process became increasingly organized, and after 4 weeks she reached her baseline status based upon family reports and the clinician’s CGI Global Improvement rating of 2 (much improved). Her auditory hallucinations resolved, and she was discharged to her family’s care.

Twice-daily blood testing was stopped at discharge. Ms. G continues to take clozapine and receives blood tests every 2 weeks, with no apparent signs of agranulocytosis.

### Table

<table>
<thead>
<tr>
<th>Adverse effect</th>
<th>Incidence rate among clozapine users</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agranulocytosis</td>
<td>3/1000 person years* at 6 months</td>
</tr>
<tr>
<td>Hepatitis</td>
<td>Less than 1%</td>
</tr>
<tr>
<td>Hyperglycemia with ketoacidosis</td>
<td>Unknown, case reports</td>
</tr>
<tr>
<td>Myocarditis</td>
<td>5.0-96.6 cases/100,000 patient years</td>
</tr>
<tr>
<td>Neuroleptic malignant syndrome</td>
<td>Unknown, several case reports</td>
</tr>
<tr>
<td>Orthostasis with cardiac collapse</td>
<td>1/3,000 cases</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>1/3,450 person years</td>
</tr>
<tr>
<td>Seizures</td>
<td>5% after 1 year of therapy</td>
</tr>
</tbody>
</table>

* Person year = 1 person taking medication for 1 year

Suggested guidelines for managing WBC counts during clozapine therapy

Is WBC >3,500/mm³?

**YES**

History of leukocytopenia, granulocytopenia, or myocarditis?

**NO**

Ineligible for clozapine therapy

**NO**

Initiate clozapine therapy at ≤25 mg/d

Test weekly for WBC/ANC

WBC >3,500/mm³ and ANC >1,500/mm³

Dispense clozapine

If WBC 3,000-3,500/mm³ or WBC decreases by 3,000/mm³ over 3 weeks:

- Recheck CBC in evening
- Monitor twice weekly until WBC >3,500/mm³ and WBC fluctuation is within a 3,000/mm³ range for 3 weeks

If WBC 2,000-3,000/mm³ or ANC 1,000-1,500/mm³:

- Recheck CBC in evening
- Suspend clozapine therapy if evening WBC <3,000/mm³
- Daily WBC with differential
- Monitor for flu-like symptoms that suggest immunosuppression
- Strongly consider GM-CSF or other augmentation method

If WBC <2,000/mm³ or ANC <1,000/mm³:

- Stop clozapine
- Admit to hospital
- STAT hematology consult
- Consider bone marrow biopsy
- Institute GM-CSF

Patient ineligble for rechallenge with clozapine without approval of hematologist and WBC augmentation

Patient may be rechallenged on clozapine after WBC >3,500/mm³ and ANC >1,500/mm³

WBC: White blood cell (count); ANC: Absolute neutrophil count; CBC: Complete blood count; GM-CSF: Granulocyte-macrophage colony-stimulating factor
CASES THAT TEST YOUR SKILLS

Clozapine therapy: Timing is everything

Box

Treatments for clozapine-related agranulocytosis

Two treatments for clozapine-dependent agranulocytosis have been described.

• Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein that has been shown to stimulate proliferation of precursor cells in bone marrow and their differentiation into granulocytes and macrophages. Researchers have reported that GM-CSF treatment allows patients to continue taking clozapine after an episode of severe neutropenia.10-12

• Lithium salts have been reported to exploit the natural leukocytosis observed with lithium to counter clozapine-related leukopenia.13 Use of lithium to displace white blood cells has been debated, and anecdotal evidence suggests that combining lithium with clozapine may increase the chance of seizure and neuroleptic malignant syndrome.4 Still, cases reported by Adityanjee and Blier suggest that lithium augmentation is cost-effective and efficacious.14,15

How could Ms. G’s doctors have avoided stopping her clozapine therapy and her subsequent decompensation?

The authors’ observations

Aggressive blood testing and cessation of clozapine therapy are indicated when onset of granulocytopenia and agranulocytosis are suspected. Even with early detection and discontinuation, the chance of infectious disease poses a danger for up to 4 weeks until WBC levels return to normal.4

Given Ms. G’s lack of response to other antipsychotics, however, we had to consider resuming clozapine therapy. Studies have described agranulocytosis management strategies that may allow patients to keep taking clozapine despite low WBC counts (Box).

We also considered the timing of Ms. G’s blood test that showed a WBC count <2,700/mm³. Ahokas16 suggests that evening WBC counts are significantly higher than those taken in the morning and that granulocytes fluctuate in a diurnal pattern. Ms. G’s evening WBC counts were on average 1,300/mm³ higher than morning levels. Allowing for this diurnal variation and comparing evening blood samples could have averted the interruption in Ms. G’s clozapine therapy and prevented relapse in a patient with highly treatment-refractory schizophrenia.

References


Low WBC counts in patients taking clozapine for treatment-refractory schizophrenia present a tough clinical challenge. Consider WBC augmentation and diurnal variations in WBC readings before stopping clozapine and risking psychotic relapse.
Check your patient files for a case that offers “lessons learned” and send it to pete.kelly@dowdenhealth.com. Keep it to 2,000 words, outlining history and treatment options, with interspersed commentary to reinforce the key points.

If you have questions before writing, contact Pete Kelly. Our editorial board and case history editor will review your article—and you’ll hear from us soon.